

CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office on November 4, 1996.

Nancy J. Robins  
NANCY J. ROBINS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Lynn E. Spitler et al.

Serial No.: 08/288,057

Filing Date: 10 August 1994

For: PROSTATIC CANCER VACCINE

Examiner: P. Gambel

Group Art Unit: 1816

RECEIVED  
MAY 07 1998  
MATRIX DISTANCE  
SERVICE CENTER

DECLARATION OF LYNN E. SPITLER  
PURSUANT TO 37 C.F.R § 1.132

Box AF  
Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

I, Lynn E. Spitler, declare as follows:

1. I am a coinventor in regard to the above-referenced patent application, and have been supervising clinical trials using antitumor vaccines which contain recombinant human prostate-specific antigen (PSA) as the active ingredient. I am an experienced immunologist and medical doctor. A copy of my *curriculum vitae* is attached hereto as Exhibit A.

2. I note that The Examiner makes the point several times that previous attempts to actively immunize patients with prostate adenocarcinoma cells admixed with adjuvant have shown little or no therapeutic benefit. However, the use of whole tumor cells is not analogous to the use of recombinant protein such as purified PSA. Whole PSA is not represented on the surface of the

tumor cells; thus, the patients would not be expected to be effectively immunized to PSA via this approach. PSA is synthesized within the tumor cells and secreted; therefore, the patients' immune system might be exposed to small amounts of PSA through this approach as some of the tumor cells die and release the internal PSA; these small amounts of antigen would be presented to the immune system in the context of all the other antigens present on and in the tumor cells. This would not be likely to result in an immune response to the PSA. Peptides derived from PSA are present on the surface of the tumor cells, presented in the context of HLA molecules. For these to induce an immune response, it would be expected that they would have to be taken up by the professional antigen presenting cells and represented on the surface of these cells. Again, this would be occurring in the presence of all the other antigens present on and in the tumor cells.

3. Thus, one cannot take failure of the approaches using whole tumor cells to indicate that immunization with specific antigens will fail (including antigens overrepresented in the prostate gland, an immunologically effective portion thereof, or an antiidiotypic antibody). Indeed, it is the recognition that the use of pure antigens may represent a more effective means of immunization for cancer therapy which has led to intense activity in this field and numerous clinical trials (Spitler, L.E., Engineered Vaccines for Cancer, *Sixth International Congress on Anti-Cancer Treatment* (1995) Paris, February 6-9, 1996; Spitler, L.E., Cancer Vaccines: The Interferon Analogy, *Cancer Biotherapy* (1995) 10:1-3 (copies attached).

4. Clinical trials in a number of patients have been initiated using recombinantly produced human PSA. PSA is a well known glycoprotein with a molecular weight of 33-34 kDa. PSA was cloned, expressed, and produced by large scale suspension cultures of High Five™ insect cells infected with recombinant PSA-baculovirus. PSA has the amino acid sequence:

D L I V G G W E C E K H S Q P W Q V L V  
A S R G R A V C G G V L V H P Q W V L T  
A A H C I R N K S V I L L G R H S L F H  
P E D T G Q V F Q V S H S F P H P L Y D

M S L L K N R F L R P G D D S S H D L M  
 L L R L S E P A E L T D A V K V M D L P  
 T Q E P A L G T T C Y A S G W G S I E P  
 E E F L T P K K L Q C V D L H V I S N D  
 V C A Q V H P Q K V T K F M L C A G R W  
 T G G K S T C S G D S G G P L V C N G V  
 L Q G I T S W G S E Q C A L P E R P S L  
 Y T K V V H Y R K W I K D T I V A N P

PSA was purified from the culture supernatants by affinity chromatography using a monoclonal antibody specific to PSA and incorporated into liposomes of the following composition:

Each ml. (one dose) contained:

Component	Quantity (mg/ml)
Prostate Specific Antigen	Approximately 0.10
Monophosphoryl Lipid A	0.20
Dimyristoyl phosphatidylcholine	61.01
Dimyristoyl phosphatidylglycerol	6.89
Cholesterol	29.00
Polysorbate 80	0.10*

Buffer: 20 mM TRIS-glycine in 140 mM NaCl

\*Maximum quantity that can be incorporated. The actual amount incorporated is unknown.

5. Six (6) patients were immunized with the prostate cancer vaccine described above. Each patient was given 1 ml of the vaccine intramuscularly, divided into 2 sites, on days 0, 30, and 60. An additional two (2) patients have been treated by intravenous administration of the product with the same dose and schedule of administration. All patients were carefully monitored for adverse effects through clinical and laboratory evaluation. No adverse event attributable to the vaccine was observed in any patient. Specifically, there were no adverse events suggesting an autoimmune reaction to cross-reacting antigens.

6. Immunologic tests of T and B cell responses were performed before each immunization and 2 weeks after each immunization. Evidence of T-cell immune responses was observed. (Harris, D.T., et al., Active Specific Immunization of Patients with Hormone-refractory Prostate Cancer using OncoVax-P™, ASCO Proceedings (1996)) (copy enclosed).

7. For immunologic testing of patients, a pool of peptides representing CTL epitopes of PSA was used:

Amino Acid Numbers	Sequence
29-37	VLVHPQWVL
98-106	MLLRLSEPA
141-150	FLTPKKLQCV
146-154	KLQCVDLHV
154-163	VISNDVCAQV

Peripheral blood mononuclear cells were harvested at the times indicated and incubated with the PSA peptide pool. On the third day of culture, Interleukin-2 (IL-2) was added. On day 7, the cultures were restimulated with autologous antigen presenting cells and the PSA peptide pool. The cultures were assayed on day 19 to determine the levels of gamma interferon and Interleukin-4 (IL-4) production. Results in the first four patients studied showed an increase in the production of these cytokines in some of the samples after immunization, as compared to before immunization, thus indicating a T-cell response. These results are shown in Exhibit B.

8. The foregoing results show that in clinical trials, the vaccine of the invention causes no adverse side effects sufficient to undermine its efficacy and that the vaccine is capable of eliciting an immune response to the PSA antigen mediated by T-cells.

9. In more detail, in regard to safety, there were no local reactions at the injection site, no symptoms of prostatitis, no signs of autoimmune disease, no malaise or fevers, and no signs of allergic reactions.

10. All of the patients had metastatic disease, had failed hormonal therapy, and had rising levels of PSA at the time of entry into the study.

11. As shown in the table below, and in Exhibit B, two of the six patients (patients no. 2 and no. 3) had immunological responses to PSA and three others had some suggestion of reaction (patients no. 1, no. 4 and no. 5). Lymphocytes from patient no. 2 showed proliferation to PSA and to PSA peptides as well as production of the cytokines  $\gamma$ -interferon and interleukin-4 in response to PSA peptides. The lymphocytes from patient no. 3 showed proliferation in response to PSA in two separate tests and this patient had a positive skin response to PSA. We were not able to measure CTLs directly because the assay is still under development; however, the cytokine production in response to PSA peptide stimulation shown in two patients is correlated with CTL development. The following table summarizes the results obtained. N.T. refers to not tested.

Immologic Responses Summary							
Patient #	PSA Skin Test	Lympho #1 PSA	Lympho #2 PSA	Lympho Peptide	Cytokine Gamma IFN	Cytokine IL-4	Antibody
1. AW	-	-	-	+/-	-	+	0
2. JH	N.T.	+	-	+	+	+	0
3. MD	+	+	+	-	-	+/-	+/-
4. MED	-	N.T.	-	-	+/-	-	0
5. HN	-	N.T.	+/-	-	N.T.	N.T.	0
6. JLB	-	N.T.	-	-	N.T.	N.T.	0

12. Exhibit C contains copies of overhead transparencies prepared for formal presentation of results of the clinical study.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

Executed at Tiburon, California on

11/1/96  
Date

Lynn E. Spitler  
Lynn E. Spitler

## CURRICULUM VITAE

LYNN E. SPITLER, M.D.

1895 Mountain View Drive  
Tiburon, California 94920

(415) 435-9861  
FAX (415) 435-6851

Social Security #366-38-1697

### Education:

University of Michigan, Ann Arbor, Michigan	1956-1959
University of Michigan Medical School Ann Arbor, Michigan M.D. (cum laude)	1959-1963

### Training:

Intern	Highland Alameda County Hospital Oakland, California	1963-1964
Resident	University of California School of Medicine San Francisco, California	1964-1966
Research Fellow	H.S. Lawrence, M.D. Department of Medicine - Immunology New York University New York, New York	1966-1967
Immunology Trainee	H. Hugh Fudenberg, M.D. University of California School of Medicine San Francisco, California	1967-1969

**Teaching Appointments and Employment:**

Instructor of Medicine in Residence University of California School of Medicine San Francisco, California 94143	1970-1971
Assistant Professor of Medicine in Residence University of California School of Medicine San Francisco, California 94143	1971-present
Research Associate Cancer Research Institute University of California School of Medicine San Francisco, CA 94143	1971-1978
Director, Melanoma Center Northern California Health Center San Francisco, California 94118	1978-1990
Director of Research Children's Hospital of San Francisco San Francisco, California 94118	1978-1981
Member, Graduate Group in Comparative Pathology Department of Comparative Pathology University of California, Davis Davis, California	1976-1981
Senior Vice President XOMA Corporation 2910 Seventh Street Berkeley, California 94710	1981-1988
Associate Scientific Director Biotherapeutics, Inc. 357 Riverside Drive Franklin, Tennessee, 37065-1676	1988-1989

Director  
Northern California Melanoma Centers  
1895 Mountain View Drive  
Tiburon, California 94920

1990-present

President  
Jenner Technologies  
1895 Mountain View Drive  
Tiburon, California 94920

1991-present

**Awards and Honors:**

Recipient: Dernham Senior Fellowship  
California Div. of the American Cancer Society

1969-1971

Recipient: Research Career Development Award  
National Institutes of Health

1971-1976

Alpha Omega Alpha (Junior year)

1961

Outstanding Young Women of America

1968

Who's Who of American Women

1972

Who's Who in the West

1973

**Board Certification:**

American Board of Internal Medicine  
American Board of Allergy and Immunology

1972

1974

**Licensure:**

Michigan	25985
New York	96454
California	C-26446

**Memberships in Professional Societies:**

American Association of Immunologists  
American Association for the Advancement of Science  
Alpha Epsilon Iota  
Western Society for Clinical Research  
American Federation of Clinical Research  
Society of Biological Therapy  
American Association for Cancer Research

**Patents:**

Patent #4,489,810 for "Composition and Method for Transplantation Therapy"  
Patent #4,590,071 for "Human Melanoma Specific Immunotoxins"

**PUBLIC SERVICE**

**National Review Committees:**

Allergy and Immunology Research Committee, NIAID, NIH	1976-1980
Merit Review Board in Immunology, VA, Washington, D.C. (Chairman 1979-1980)	1976-1980

**Editorial Boards:**

The Journal of Immunology	1975-1978
The International Journal of Immunopharmacology	1979-1984
Immunologia Clinica e Sperimentale	1982-1986
Antibody Immunoconjugates and Radiopharmaceuticals (Associate Editor)	1987-present
Molecular Biotherapy	1987-present
Cancer Biotherapy	1991-present

### Manuscript Reviews:

American Review of Respiratory Disease  
Annals of Allergy  
Annals of Internal Medicine  
Archives of Dermatology  
Archives of Internal Medicine  
California Medicine  
Cancer  
Cancer Immunology and Immunopathology  
Cancer Research  
Cellular Immunology  
Chest  
Infection and Immunity  
Infectious Disease and Immunology  
International Journal of Immunopharmacology  
Journal of Clinical Investigation  
Journal of Immunology  
Journal of Infectious Diseases  
Journal of the American Academy of Dermatology  
Molecular Biotherapy  
Nature  
New England Journal of Medicine  
Science  
The Western Journal of Medicine

### Special Consultant:

National Institutes of Health Grant Reviews  
National Institutes of Health Site Visits  
United States Tuberculosis Panel Task Group  
Atomic Energy Commission Site Visits  
Public Education Panel, National Multiple Sclerosis Society  
Review of Grant Applications for the National Science Foundation  
Enterprise for High School Students, Medical Apprenticeship Program,  
San Francisco, California  
Board of Directors, San Francisco Unit, American Cancer Society  
Research and Human Experimentation Committee, Children's Hospital  
of San Francisco  
U.S. Energy Research Development Administration Site Visits

## BIBLIOGRAPHY

(Excluding Abstracts)

LYNN E. SPITLER, M.D.

1. Spitler L.E., Cochrum K.C., and Fudenberg H.H.: Mycoplasma inhibition of phytohemagglutinin stimulation of lymphocytes. Science 161:1148-1149, 1968.
2. Spitler L.E., Huber H., and Fudenberg H.H.: Inhibition of capillary migration by antigen-antibody complexes. J. Immunol. 102:404-411, 1969.
3. Cochrum K.D., Spitler L.E., Najarian J.S., and Fudenberg H.H.: A new source of large numbers of lymphocytes and studies on their culture. In Proceedings of the Third Annual Leukocyte Culture Conference. Edited by W.O. Rieke, Appleton-Century-Crofts, New York, New York, 1969, pp. 169-175.
4. Spitler L.E., and Lawrence H.S.: Studies of lymphocyte culture; products of sensitive lymphocyte-antigen interaction. J. Immunol. 103:1072-1077, 1969.
5. Spitler L.E., Benjamini E., Young J.D., Kaplan H., and Fudenberg H. H.: Studies on the immune response to a characterized antigenic determinant of the tobacco mosaic virus protein. J. Exp. Med. 131:133-148, 1970.
6. Spitler L.E., and Fudenberg H.H.: Multiple antibody response following busulfan therapy. Vox Sang. 18:450-458, 1970.
7. Spitler L.E., and Fudenberg H.H.: Products of interaction of antigen-sensitive leukocytes and antigen: further characterization of the mitogenic factor. J. Immunol. 104:544-549, 1970.
8. Levin A.S., Spitler L.E., Stites D.P., and Fudenberg H.H.: Wiskott-Aldrich syndrome: a genetically determined cellular immunological deficiency. Clinical and laboratory responses to therapy with transfer factor. Proc. Natl. Acad. Sci. 67:821-827, 1970.
9. Spitler L.E., Keuppers F., and Fudenberg H.H.: Normal macrophage function in pulmonary alveolar proteinosis. Am. Rev. Resp. Dis. 102:975-977, 1970.

10. Spitler L.E., Levin A.S., Huber H., and Fudenberg H.H.: Prediction of results of transfer factor therapy in the Wiskott-Aldrich syndrome by monocyte IgG receptors. In Proceedings of the Sixth Leukocyte Culture Conference. Edited by M.R. Schwartz. Academic Press, Inc., New York and London, 1972, pp. 795-803.
11. Henderson W.R., Fukuyama K., Epstein W.L., and Spitler L.E.: In vitro demonstration of delayed hypersensitivity in patients with berylliosis. J. Invest. Dermatol. 58:5-8, 1972.
12. Senyk G., Nitecki D.E., Spitler L.E., and Goodman J.W.: The immune response to glucagon in conjugated form. Immunochemistry 9:79-110, 1972.
13. Henderson W.R., Fukuyama K., Epstein W.L., and Spitler L.E.: Demonstration of cellular immunity to tumor-specific antigens of malignant melanoma in hamsters by inhibition of macrophage migration. J. Invest. Dermatol. 58:299-332, 1972.
14. Spitler L.E., Von Muller C., Fudenberg H.H., and Eylar E.A.: Experimental allergic encephalitis: dissociation of cellular immunity to brain protein and disease production. J. Exp. Med. 136:156-174., 1972.
15. Fudenberg H.H., Spitler L.E., and Levin A.S.: Treatment of immune deficiency. Ann. N.Y. Acad. Sci. 69:529-535, 1972.
16. Hitzig W.H., Font Anellaz H.P., Muntener U., Paul S., Spitler L.E., and Fudenberg H.H.: Transfer factor: immunologische Grundlagen und therapeutische Erfahrungen. Schweizerische Medizinische Wochenschrift 102:1237, 1972.
17. Spitler L.E., Levin A.S., Stites D.P., Fudenberg H.H., Pirofsky B., August C.S., Steinhilber E.R., Hitzig W.H., and Gatti R.A.: The Wiskott-Aldrich syndrome: results of transfer factor therapy. J. Clin. Invest. 51:3216-3224, 1972.
18. Lieber E., Hsu L., Spitler L.E., and Fudenberg H.H.: Cytogenetic findings in a parent of a patient with Fanconi's anemia. Clin. Genet. 3:357-363, 1972.
19. Spitler L.E., Levin A.S., and Fudenberg H.H.: Human lymphocyte transfer factor. In Methods in Cancer Research, vol. 8. Edited by H. Busch, Academic Press, New York, 1973, pp. 59-106.
20. Henderson W.R., Fukuyama K., Epstein W.L., and Spitler L.E.: Blocking of a cellular immune reaction to malignant melanoma by immunoglobulin from tumor-bearing animals. J. Reticul. Soc. 13:155-160, 1973.

21. Epstein W.L., Sagebiel R., Spidler L.E., Wybran J., Reed W., and Blois M.S.: Halo nevi and melanoma. JAMA 225:373-377, 1973.
22. Mozar H.n., Finnigan F.B., Petzoid H., Spidler L.E., Emmons R.W., and Rothenberg B.: Myelopathy following duck embryo rabies vaccine. JAMA 224:1605-1607, 1973.
23. Astor S.H., Spidler L.E., Frick O.L., and Fudenberg H.H.: Human leukocyte migration inhibition in agarose using four antigens: correlation with skin reactivity. J. Immunol. 110:1174-1179, 1973.
24. Levin A.S., Spidler L.E., and Fudenberg H.H.: Transfer factor therapy in immune deficiency states. Ann. Rev. Med. 24:175-208, 1973.
25. Spidler L.E., Levin A.S., and Fudenberg H.H.: Agammaglobulinemia absent delayed sensitivity and lymphopenia without infections: demonstration of immunologic unknowns. Am. J. Med. 54:371-377, 1973.
26. Bloom B.R., Ceppellini R., Cetottini J.C., David J.R., Kunkel H., Landy M., Lawrence H.S., Maini R., Nussenzweig V., Perlman P., Spidler L.E., Rosen F., and Zabriskie J.: In vitro methods of cell-mediated immunity: a progress report. Cell. Immunol. 6:331-347, 1973.
27. Levin A.S., Spidler L.E., and Fudenberg H.H.: Immune deficiency states. In Introduction to Clinical Allergy. Edited by B. Finegold, C.C. Thomas, Springfield, Illinois, 1973, pp. 346-359.
28. Hoffman P.M., Gaston D.D., and Spidler L.E.: Comparison of experimental allergic encephalomyelitis induced with spinal cord, basic protein, and synthetic encephalitogenic peptide. Clin. Immunol. and Immunopath. 1:364-371, 1973.
29. Wybran J., Levin A.S., Spidler L.E., and Fudenberg H.H.: Rosette-forming cells, immunologic deficiency diseases and transfer factor. New Engl. J. Med. 288:710-713, 1973.
30. Feigin R.D., Shackelford P.G., Eisen S., Spidler L.E., Pickering L.K., and Anderson D.C.: Treatment of mucocutaneous candidiasis with transfer factor. Pediatrics 53:63-70, 1974.
31. Spidler L.E., Levin A.S., and Fudenberg H.H.: Transfer factor. In Clinical Immunobiology, vol. 2. Edited by F.H. Bach and R.A. Good, Academic Press, New York, 2:153-175, 1974.
32. Fudenberg H.H., Levin A.S., Spidler L.E., Wybran J., and Byers V.: The therapeutic uses of transfer factor. Hosp. Prac. 9:95-104, 1974.

33. Catanzaro A., Spidler L.E., and Moser K.M.: Immunotherapy of coccidioidomycosis. J. Clin. Invest. 54:690-701, 1974.
34. Valdimarrson H., and Spidler L.E. (Chairman): Transfer factor, clinical application. In Progress in Immunology II, vol. 5. Edited by L. Brent and J. Holborow. North Holland Publication Company, Amsterdam, 1974, pp. 377-382.
35. Spidler L.E., Wybran J., Lieberman R., Levinson D., Epstein W., and Hendrickson C.. Results of intra-lesional BCG therapy in malignant melanoma: clinical and immunologic evaluation and complications. In Neoplasm Immunity: BCG Vaccination, Proceedings of a Chicago Symposium. Edited by R.G. Crispen, Institute for Tuberculosis Research, University of Illinois, Chicago, 1974, pp. 45-48.
36. Spidler L.E., Von Muller C. M., and Young J.D.: Experimental allergic encephalitis, study of cellular immunity to the encephalitogenic determinant. Cell. Immunol. 15:143-151, 1975.
37. Spidler L.E.: Transfer factor. Cutis Magazine 15:420-423, 1975.
38. Levin A.S., Byers V.S., Fudenberg H.H., Wybran J., Hackett A.J., Johnston J.O., and Spidler L.E.: Osteogenic sarcoma: immunologic parameters before and during immunotherapy with tumor-specific transfer factor. J. Clin. Invest. 55:487-499, 1975.
39. Catanzaro A., Spidler L.E., and Moser K.M.: Cellular immune response in coccidioidomycosis. Cell. Immunol. 15:360-371, 1975.
40. Spidler L.E., Spath P., Cooper N., and Fudenberg H.H.: Phagocytes and C4 in paraproteinemia. Brit. J. Haemat. 29:279-292, 1975.
41. Levin A.S., Spidler L.E., and Fudenberg H.H.: Transfer factor I: methods of therapy. In Immunodeficiency in Man and Animals: Birth Defects: Original Article, Series II. Edited by D. Bergsma. Sinauer Associates, Publishers, Sunderland, Massachusetts, 1975, pp. 445-448.
42. Spidler L.E., Levin A.S., and Fudenberg H.H.: Transfer factor II: results of therapy. In Immunodeficiency in Man and Animals: Birth Defects: Original Article, Series II. Edited by D. Bergsma. Sinauer Associates, Publishers, Sunderland, Massachusetts, 1975, pp. 449-456.

43. McKhan C.F., Hendrickson C.G., Spidler L.E., Gunnarsson A., Banerjee D., and Nelson W.R.: Immunotherapy of melanoma with BCG: two fatalities following intra-lesional injection. Cancer 35:514-520, 1975.
44. Hoffman P.M., Spidler L.E., Hsu M., and Fudenberg H.H.: Leukocyte migration inhibition in agarose. Cell. Immunol. 18:21-30, 1975.
45. Devich K.B., Lee J.C., Epstein W.L., Spidler L.E., and Hopper J., Jr.: Renal lesions accompanying poison oak dermatitis. Clin. Nephrol. 3:106-113, 1975.
46. Spidler L.E., Levin A.S., Stites D.P., Fudenberg H.H., and Huber H.: The Wiskott-Aldrich syndrome, immunologic studies in nine patients and selected family members. Cell. Immunol. 19:210-218, 1975.
47. Catanzaro A., and Spidler L.E.: Transfer factor in diseases of the lung. In Immunologic and Infectious Reactions in the Lung. Edited by C.H. Kirkpatrick and H.Y. Reynolds. Marcel Dekker, New York, 1976, pp. 519-548.
48. Fidler I.J., and Spidler L.E.: The effects of levamisole on in vivo and in vitro murine host response to syngeneic transplantation tumor. J. Natl. Cancer Inst. 55:1107-1112, 1975.
49. Olson J.A., Nelms D.C., Silverman S., and Spidler L.E.: Levamisole, a new treatment for recurrent aphthous stomatitis. Oral Surg., Oral Med., Oral Path. 41:588-600, 1976.
50. Welch T.M., Triglia R., Spidler L.E., and Fudenberg H.H.: Preliminary studies on human "transfer factor" activity in guinea pigs: systemic transfer of cutaneous delayed-type hypersensitivity to PPD and SKSD. Clin. Immunol. Immunopathol. 5:407-415, 1976.
51. Hoffman P.M., Spidler L.E., and Hsu M.: Leukocyte migration inhibition in guinea pigs. 1. Correlation with skin test reactivity and macrophage-migration inhibition. Cell. Immunol. 21:358-363, 1976.
52. Spidler L.E., Levin A.S., and Wybran J.: Combined immunotherapy in malignant melanoma: regression of metastatic lesions in two patients concordant in timing with systemic administration of transfer factor and bacillus Calmette-Guerin. Cell. Immunol. 21:1-19, 1976.
53. Levinson A.I., Hopewell P.C., Stites D.P., Spidler L.E., and Fudenberg H.H.: Co-existent lymphoid interstitial pneumonia, pernicious anemia, and agammaglobulinemia. Comment on autoimmune pathogenesis. Arch. Intern. Med. 136:312-316, 1976.

54. Spitler L.E.: Delayed hypersensitivity skin testing. In Manual of Clinical Immunology. Edited by N.R. Rose and H. Friedman. American Society for Microbiology, Washington, D.C., 1976, pp. 53-63.
55. Catanzaro A., and Spitler L.E.: For the Coccidioidomycosis Cooperative Treatment Group: Clinical and immunologic results of transfer factor therapy in coccidioidomycosis. In Transfer Factor Basic Properties and Clinical Applications. Edited by M.S. Ascher, A.A. Godieb and C.H. Kirkpatrick, Academic Press, New York, 1976, pp 477-491.
56. Spitler L.E.: Malignant melanoma. J. Invest. Dermatol. 67:435-441, 1976.
57. Dau P.C., Johnson K.P., and Spitler L.E.: The effect of levamisole on cellular immunity in multiple sclerosis. Clin. Exp. Immunol. 26:302-309, 1976.
58. Wybran J., Spitler L.E., Lieberman R., and Fudenberg H.H.: "Active" T-cell rosettes and total T-rosettes in patients with melanoma following intratumoral inoculation of BCG: a clue to the mechanism of action of baccillus Calmette-Guerin? Cancer Immunol. Immunother. 1:153-156, 1976.
59. Triglia R., and Spitler L.E.: Human "transfer factor" activity in guinea pigs. Further studies. In Transfer Factor Basic Properties and Clinical Applications. Edited by M.S. Ascher, A.A. Gottlieb and C.H. Kirkpatrick, Academic Press, New York, 1976, pp. 695-703.
60. Spitler L.E., and Von Muller C.: Leukocyte migration inhibition in agarose. In In Vitro Methods in Cell-Mediated and Tumor Immunity. Edited by B. Bloom and J.R. David. Academic Press, New York, 1976, pp. 645-650.
61. Stevens D.A., et al.: (Coccidioidomycosis Cooperative Treatment Group): Transfer factor therapy of infectious diseases. In Advances in Dermatopharmacology (Chapter 6). Edited by P. Frost, E.C. Gomez and N. Zaias, Spectrum Publications, 1977, pp. 67-74.
62. Spitler L.E., Glogau R., Nelms D., Silverman S., Jr., Olson J., O'Conner R., Ostler H., Smolin G., Basch K., Wong P., Engleman E.P., and Brugmans J.: Clinical and immunological effects of levamisole. In Modulation of Host Immune Resistance in the Prevention or Treatment of Induced Neoplasias. (Fogarty International Center Proceedings 28). Edited by M.A. Chirigos, U.S. Government Printing Office, Washington, D.C., 1974, pp. 71-75.
63. Ibrahim A.B, Triglia R., Dau P.C., and Spitler L.E.: Anti-tumor effects of levamisole on an allogeneic hamster melanoma and a syngeneic rat hepatoma. In Progress in Cancer

- Research, vol. 2. Control of Neoplasia by Modulation of the Immune System. Edited by M.A. Chirigos, Raven Press, New York, 1977.
64. Spitler L.E., and Dau P.C.: Immunotherapy in infectious disease, autoimmunity and cancer. Acta Neurol. Scand. (Suppl. 63):227-233, 1977.
  65. Spitler L.E., Glogau R.G., Nelms D.C., Basch C.M., Olson J.A., Silverman S., Jr., and Engleman E.P.: Clinical and immunologic effects of levamisole. In Progress in Cancer Research, vol. 2. Control of Neoplasia by Modulation of the Immune System. Edited by M.A. Chirigos, Raven Press, New York, 1977, pp. 217-225.
  66. Spitler L.E., Littooy F.N., and Sgebiel R.W.: Cellular immunity in patients with malignant melanoma and their household contacts. Cancer Immunol. Immunother. 2:69-76, 1977.
  67. Silverman S., Jr., Olson J.A., Nelms D.C., and Spitler L.E.: Recurrent aphthous stomatitis: current status of etiology and treatment. J. Calif. Dental Assoc. 2/1977, pp. 38-44.
  68. Wolf R.E., Fudenberg H.H., Welch T.M., Spitler L.E., and Ziff M.: Treatment of Bechet's syndrome with transfer factor. JAMA 238:869-871, 1977.
  69. Spivack S.D., Spitler L.E., and Dunphy J.E.: Oncology and cancer chemotherapy. In Current Surgical Diagnosis and Treatment. Edited by J.E. Dunphy and L.W. Way, Lange Medical Publications, Los Altos, California, 1977, pp. 1059-1082.
  70. Dau P.C., Lindstrom J.M., Cassel C.K., Denys E.H., Shev E.E., and Spitler L.E.: Plasmapheresis and immunosuppressive drug therapy in myasthenia gravis. New Engl. J. Med. 297:1134-1140, 1977.
  71. Berkel A.I., Ersoy F., Epstein L.B., and Spitler L.E.: Transfer factor therapy in ataxia-telangiectasia. Clin. Exp. Immunol. 29:376-384, 1977.
  72. Basch C.M., Spitler L.E., Engleman E.G., and Engleman E.P.: Cellular immune reactivity in patients with rheumatoid arthritis and effects of levamisole. J. Rheumatol. 4:377-388, 1977.
  73. Spitler L.E.: Transfer factor. Int. J. Dermatol. 17:445-458, 1978.
  74. Spitler L.E., Sagebiel R.W., Wong P.P., Malm T.M., Chase R.H., and Gonzalez R.L.: A randomized double-blind trial of adjuvant therapy with levamisole versus placebo in patients with malignant melanoma. In Progress in Cancer Research and Therapy, vol. 6.

Immunotherapy of Cancer: Present Status of Trials in Man. Edited by W.D. Terry and D. Windhorst, Raven Press, New York, 1978, pp. 73-79.

75. Spidler L.E., Wong P., and Sagebiel R.: Combined immunotherapy of malignant melanoma-unusual survival following cerebral metastasis. Arch. Dermatol. 114:1501, 1978.
76. Gross P.A., Patel C., and Spidler L.E.: Disseminated cryptococcus treated with transfer factor. JAMA 240:2460-2462, 1978.
77. Suquet Von Muller C., Spidler L.E., and LeCocq J.: Experimental allergic encephalitis. study of cellular immunity during disease suppression. Eur. J. Immunol. 8:771-776, 1978.
78. Spidler L.E.: Transfer factor. In Handbook Series in Clinical Laboratory Science. Section F: Immunology, vol. 1, part 1. Edited by A. Baumgarten and F.F. Richards, CRC Press, West Palm Beach, Florida, 1978, pp. 87-106.
79. Gonzalez R.L., Spidler L.E., and Sagebiel R.W.: Effect of levamisole as a surgical adjuvant therapy for malignant melanoma. Cancer Treatment Reports 62:1703-1707, 1978.
80. Spidler L.E., Mischak R., and Basch C.: Pharmacological modification of suppressor cell activity. In The Pharmacology of Immuregulation. Edited by G.H. Werner and F. Floch, Academic Press, New York, 1978, pp. 239-251.
81. Mischak R.P., Dau P.C., Gonzalez R.L., and Spidler L.E.: In vitro testing of suppressor cell activity in myasthenia gravis. In International Conference on Plasmapheresis and the Immunobiology of Myasthenia Gravis. Edited by P.C. Dau; Clark, Houghton, Mifflin, New York, 1979, pp. 72-78.
82. Gonzalez R.L., Wong P., and Spidler L.E.: Altered regulation of mitogen responsiveness by suppressor cells in multiple sclerosis. Clin. Exp. Immunol. 36:78-84, 1979.
83. Jonas S., Wichter M., and Spidler L.E.: Amytrophic lateral sclerosis: failure of transfer factor therapy. Ann. Neurol. 67:59-66, 1979.
84. Spidler L.E.: Transfer factor therapy in the Wiskott-Aldrich syndrome: results of long-term follow-up in 32 patients. Am. J. Med. 67:59-66, 1979.
85. Spivack S.D., Spidler L.E., Holm D.C., and Dunphy J.E.: Oncology and cancer chemotherapy. In Current Surgical Diagnosis and Treatment (Chapter 49). Edited by S.D.

Spivack and L.W. Way, Lange Medical Publications, Los Altos, California, 1979, pp. 1073-1101.

86. Spitler L.E.: Transfer factor in immunodeficiency diseases. Ann. N.Y. Acad. Sci. 332:228-235, 1979.
87. Gonzalez R.L., Wong P., and Spitler L.E.: Adjuvant immunotherapy with transfer factor with melanoma metastatic to lung. Cancer 45:57-63, 1980.
88. Spitler L.E.: Transfer factor: Failure to transfer reactivity in normal human subjects. Clin. Exp. Immunol. 39:708-716, 1980.
89. Spitler L.E.: BCG, levamisole, and transfer factor in the treatment of cancer. In Current Cancer Immunology, Progress in Experimental Tumor Research, vol. 25. Edited by V. Richards, Karger Publications, New York, 1980, pp. 178-193.
90. Lozada F., Spitler L.E., and Silverman S., Jr.: Results of immunologic testing in patients with erythema multiforme. J. Dent. Res. 59:567-572, 1980.
91. Lozada R., Spitler L.E., and Silverman S., Jr.: Clinical immunologic responses to levamisole in 13 patients with erythema multiforme. Int. J. Immunopharmacol. 2:63-68, 1980.
92. Spitler L.E., Wray B.B., Mogerman S., Miller, III, J.J., O'Reilly R.J., and Lagios M.: Nephropathy in the Wiskott-Aldrich syndrome. Pediatrics, vol. 66, pp. 391-398, 1980.
93. Spitler L.E., and Sagebiel R.W.: A randomized trial of levamisole versus placebo as adjuvant therapy in malignant melanoma. New Engl. J. Med. 303:1143-1147, 1980.
94. Spitler L.E.: Delayed hypersensitivity skin testing. In Manual of Clinical Immunology, 2nd edition. Edited by N.R. Rose and H. Friedman. American Society of Microbiology, Washington, D.C., 1980, pp. 200-212.
95. Owen R.L., Dau P.C., Johnson K.P., and Spitler L.E.: Immunologic mechanisms in multiple sclerosis: exacerbation by type A hepatitis and by skin test antigens. JAMA 244:2307-2309, 1980.
96. Fisher G.L., Spitler L.E., McNeil K.L., and Rosenblatt L.S.: Serum copper and zinc levels in melanoma patients. Cancer 47(7):1837-1844, 1981.

97. de Merieux P., Spidler L.E., and Paulus H.E.: Treatment of Bechets syndrome with levamisole. Arth. Rheu. 24(1):64-70, 1981.
98. Catanzaro A., Spidler L.E., Campbell G.D., and Moser K.M.: Transfer factor for histoplasmosis in a patient with Hodgkin's disease. Arch. Intern. Med. 141:533-537, 1981.
99. Spidler L.E., Sagebiel R.W., Allen R., Minor D., Dymott C., and Drake T.: Levamisole in the treatment of melanoma. Immunother. Human Cancer, section VI, pp. 289-291, 1982.
100. Spidler L.E., and Scott C.F.: Immunotherapy of melanoma. In Melanoma Antigens and Antibodies. Edited by R.A. Reisfeld and S. Ferrone, Plenum Press, New York and London, 1982, pp. 355-363.
101. Spidler L.E., and Scott C.F.: Lymphocytotoxic antibody in multiple sclerosis: activity against T-cell subsets and correlation with disease activity. In Clin. Exp. Immunol. 53:133-139, 1983.
102. Scott C.F., Cashman N., and Spidler L.E.: Experimental allergic encephalitis: treatment with drugs which alter CNS serotonin levels. J. Immunopharmacol. 4(3):153-162, 1982-83.
103. Levy J.A., Lee H.M., Kawahata R.T., and Spidler L.E.: Purification of monoclonal antibodies from mouse ascites eliminates contaminating infectious mouse type C virus and nucleic acids. In Clin. Exp. Immunol. 56:114-120, 1984.
104. Engelstad B., Khentigan A., and Spidler L.E.: Clinical radioimmunoimaging. In Diagnostic Radiology. Edited by A. Margulis and C. Gooding, RREF Press, San Francisco, 1985, pp. 525-532.
105. Spidler L.E.: Removal of xenotropic and ecotropic viruses by purification of monoclonal antibodies. In Abnormal Cells, New Products and Risk. (In vitro cellular and developmental biology. Monograph;n.6). Proceedings of a workshop held July 30-31, 1984 at the National Institutes of Health, Bethesda, Maryland. Edited by H.E. Hopps and J.C. Petricciani, Tissue Culture Association, Gaithersburg, MD, 1985, pp.121-134.
106. Englestad B.L., Spidler L.E., del Rio M., Ramos E.C., Rosendorf L.L., Reinhold C.E., Khentigan A., Huberty J.P., Corpuz S.W., Lee H.M., Okerlund M.D., Hamner R.S., and Scannon P.J.: Phase I immunolymphoscintigraphy with an indium 111-labeled-antimelanoma monoclonal antibody. Radiology 161:419-422, 1986.

107. Engelstad B.C., Ramos E.C. Stoudemire J., O'Connell J.W., Villanueva J., Faulkner D.B., Hamner R.S., Spidler L.E., and Scannon P.: Improved immunospecificity in monoclonal radioimmunoimaging using dual radionuclide color functional maps. Investigative Radiology 21:917-921, 1986.
108. Spidler L.E.: Immunotoxin therapy of malignant melanoma. Med. Oncol. & Tumor Pharmacother. 3:147-152, 1986.
109. Spidler L.E., del Rio M., Khentigan A., Wedel N.I., Brophy N.A., Miller L., Harkonen W.S., Rosendorf L., Lee H.M., Mischak R.P., Kawahata R.T., Stoudemire J.B., Fradkin L.B., Bautista E.E., and Scannon P.J.: Therapy of patients with malignant melanoma using a monoclonal antimelanoma antibody-ricin A chain immunotoxin. Cancer Research 47:1717-1723, 1987.
110. Harkonen S., Stoudemire J., Mischak R.P., Spidler L.E., Lopez H., and Scannon P.: Toxicity and immunogenicity of monoclonal antimelanoma antibody ricin A chain immunotoxin in rats. Cancer Research 47:1377-1382, 1987.
111. Spidler L.E.: Phase I clinical trials with immunotoxins. Immunoconjugates: Antibody Conjugates in Radioimaging and Therapy of Cancer. Edited by C.W. Vogel, Oxford University Press, New York, 1987, pp.290-300.
112. Hertler, R.A., Spidler, L.E., and Frankel, A.E.: Humoral immune response to ricin A chain immunotoxin in patients with metastatic melanoma. Cancer Drug Delivery 4:245 - 253, 1987
113. Miller L.L, Spidler L.E., Allen R.A., and Minor D.R.: A randomized, double-blind, placebo controlled trial of transfer factor as adjuvant therapy for malignant melanoma. Cancer, 61:1543-1549, 1988.
114. Spidler, L.E.: Clinical Studies: Solid Tumors. Immunotoxins. Edited by Arthur E. Frankel, Martinus Nijhoff B.V., Boston, 1988 pp. 491-512.
115. Spidler L.E., and Miller L.: Clinical trials of transfer factor in malignancy. J. Exp. Pathol. 3:549-564, 1988
116. Harkonen S., Scannon P., Mischak R.P., Spidler L.E., Foxall C., Kennedy D., and Greenberg R.: Phase I study of a murine monoclonal anti-lipid A antibody in bacteremic and non-bacteremic patients. Antimicrobial Agents and Chemotherapy, 710-716, 1988.

117. LoBuglio A.F., Khazaeli M.B., Lee J., Haynes A., Sumerel L., Mischak R.P., and Spidler L.E. Pharmacokinetics and immune response to Xomazyme-Mel in melanoma patients. Antibody Immunoconjugates and Radiopharmaceuticals 1:305 - 310, 1988.
118. Spidler, L.E., Mischak, R. and Scannon, P.: Therapy of metastatic malignant melanoma using Xomazyme-Mel, a murine monoclonal antimelanoma ricin A chain immunotoxin. Nuclear Medicine and Biology International Journal of Applied Radiation and Isotopes, Part B, 16(6):625-627, 1989.
119. Spidler, L.E.: Monoclonal Antibodies In the Treatment of Malignant Melanoma. The Present and Future Role of Monoclonal Antibodies in the Management of Cancer. Frontiers of Radiation Therapy and Oncology, 24, 186-193, 1989
120. Mischak, R.P., Foxall, C., Rosendorf, L.L., Knebel, K., Scannon, P.J., Spidler, L.E.: Human antibody responses to components of the monoclonal antimelanoma antibody ricin A chain immunotoxin Xomazyme [registered trademark] - MEL. Molecular Biotherapy, 2:104-109, 1990.
121. Stoudemire, J.B., Mischak, R., Foxall, C., Harkonen, W.S., Del Rio, M., and Spidler, L.E.: The effects of cyclophosphamide on the toxicity and immunogenicity of ricin A chain immunotoxin in rats. Molecular Biotherapy, 2: 179-184, 1990.
122. Oratz, R., Speyer, J.L., Wernz, J.C., Hochster, H., Meyers, M., Mischak, R., and Spidler, L.E.: Antimelanoma monoclonal antibody - ricin A chain immunoconjugate (XMMME-0001-RTA) plus cyclophosphamide in the treatment of metastatic malignant melanoma: Results of a phase II trial. J. Biol Response Mod., 9(4): 345-354, 1990.
123. Spidler, L.E.: Immunotoxins. In: Principles of Cancer Biotherapy. Edited by R.K. Oldham, Marcel Dekker, inc., New York, pp 433-456, 1991.
124. Spidler, L.E.: A randomized trial of levamisole versus placebo as adjuvant therapy in malignant melanoma. Journal of Clinical Oncology, 9: 736-740, 1991.
125. Gonzalez, R., Salem, P., Bunn Jr., P.A., Zukiwski, A.A., Lamb, R., Benjamin, R.S., Spidler, L., Wedel, N., and Robinson, W.A. Single-dose murine monoclonal antibody ricin A chain immunotoxin in the treatment of metastatic melanoma: a phase I trial. Mol. Biother., 3:192-196, 1991.
126. Spidler, L.E., Conjugated Antibodies: Immunotoxins. In Antibody Therapy of Cancer. Edited by Robert Dillman, Marcel Dekker, New York, In Press, 1992.

127. Spitler, L.E. and Munoz, A.: Value of percentage of lymphocytes and active rosettes in determination of prognosis in malignant melanoma. In preparation, 1992.
128. Spitler, L.E., Von Wussow, P., Carey, R.W., Borden, E., Benjamin, R.S., Oratz, R., Tseng Jr., A., Mastrangelo, M., and Ernstoff, M.S.: Phase II Trial of a monoclonal antimelanoma antibody Ricin A chain immunotoxin in therapy of malignant melanoma. Journal of Clinical Oncology, in preparation.
129. Spitler, L.E., and Minor, D.R.: Monoclonal antimelanoma ricin A chain immunotoxin therapy of metastatic melanoma in an outpatient setting. Journal of Clinical Oncology, in preparation.

*Revised January, 1992*

# Gamma Interferon production after peptide stimulation of lymphocytes




Exhibit B

# IL-4 production after peptide stimulation of lymphocytes




Exhibit B